Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTP-HepB-IPV-Hib vaccine
- Development stage
- Approved
- Lead developer
- LG Chem
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The DTP-HepB-IPV-Hib vaccine is a hexavalent combination immunization designed to protect against six serious childhood diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis (polio), and invasive disease caused by Haemophilus influenzae type b. It contains inactivated or subunit antigens for each pathogen. The mechanism of action is immunostimulation—eliciting protective immune responses against all included pathogens. This combination reduces the number of injections required in early childhood vaccination schedules and has demonstrated safety and effectiveness in clinical trials and post-marketing surveillance[1][5][8]. The primary indication is the prevention of these six diseases in infants and young children.
- Brand names
- VaxelisInfanrix hexa
- Other names
- Diphtheria-Tetanus-Pertussis-Hepatitis B-Inactivated Poliovirus-Haemophilus influenzae type b vaccine6-in-1 vaccineDTaP/IPV/Hib/HepB vaccine
Beyond the preview
Go deeper on DTP-HepB-IPV-Hib vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTP-HepB-IPV-Hib vaccine.